Sareum : Result of AGM

SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Results of AGM

Cambridge, UK, 16 December 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, held its Annual General Meeting ("AGM") today and all resolutions were duly passed. Details of the proxy voting are shown in the table below.

Ordinary resolutions	Votes For	%	Votes Against	%	Votes Total	% of ISC Voted	Votes Withheld
1. Receive and adopt Report of the Directors and financial statements for the year	139,633,376	99.8	240,000	0.2	139,873,376	4.1	314,311
2. Receive and adopt Renumeration Committee report for the year	139,046,887	99.4	724,500	0.5	139,771,387	4.1	416,300
3. Re-elect Clive Birch as Director of the Company	138, 886,944	99.3	825,424	0.6	139,712,368	4.1	475,319
4. Re-elect Michael Owen as a Director of the Company	138,886,944	99.3	825,424	0.6	139,712,368	4.1	475,319
5. Appoint Shipleys LLP as auditor	139,141,640	99.5	320,015	0.3	139,461,655	4.1	726,032
6. Directors' authority to allot new shares	134,116,471	95.9	1,414,362	1.0	135,530,833	4.0	4,656,854
Special Resolution
7. Directors' authority to allot equity securities for cash	138,495,068	99.0	1,326,587	0.9	139,821,655	4.1	366,032

ISC - Issued Share Capital

The full text of each of the resolutions is set out in the Notice of AGM, available in the Investors section of the Company's website (www.sareum.com/investors)

For further information, please contact:

Sareum Holdings plc Tim Mitchell, CEO	01223 497 700
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman	020 7409 3494
Peel Hunt LLP (Joint Corporate Broker)
James Steel	020 7418 8900
Hybridan LLP (Nominated Broker) Claire Noyce	020 3764 2341
MEDiSTRAVA Consulting (Financial PR) Mark Swallow/ David Dible	020 3928 6901

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com